GC
MDCO

Grimes & Company’s Medicines Co MDCO Stock Holding History

Grimes & Company’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,000
Closed -$250K – 278
2019
Q3 		$250K Buy
+5,000
New +$199K 0.02% 218

Other funds holding MDCO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Grimes & Company's MDCO Position: Q4 2019 in Review

Grimes & Company sold out of Medicines Co (MDCO) in Q4 2019, closing a stake of 5,000 shares — an estimated $250K sold.

Grimes & Company first reported a position in MDCO in Q3 2019 and held it in 1 quarter. The position peaked at $250K in Q3 2019. 284 funds tracked by Wall St. Rank hold MDCO as of Q4 2019.

  • Grimes & Company reported no remaining Medicines Co position as of Q4 2019 after selling out during the quarter.
  • Grimes & Company sold 5,000 Medicines Co shares in Q4 2019, an estimated $250K.
  • Grimes & Company first reported a position in Medicines Co in Q3 2019 and held it in 1 quarter.
  • Grimes & Company's Medicines Co position peaked at $250K in Q3 2019.
  • 284 funds tracked by Wall St. Rank held Medicines Co as of Q4 2019.

Based on Grimes & Company's 13F filing for Q4 2019, filed 5 Feb 2020.